uid	pubdate	authors	title	fulljournalname	elocationid
40524977	2025 Oct	Li P, Xie Y, Wang J, Bao C, Duan J, Liu Y, Luo Q, Xu J, Ren Y, Jiang M, Li J, Guo H, Zhao H, Wang G, Liang Y, Lu W	Corrigendum to "Gene engineered exosome reverses T cell exhaustion in cancer immunotherapy" [Bioact. Mater. 34 (2024) 466-481].	Bioactive materials	doi: 10.1016/j.bioactmat.2025.05.019
40524802	2025 Jun	Kim J, Bang YH, Park S, Jung HA, Sun JM, Ahn JS, Ahn MJ, Jeon YJ, Lee J, Cho JH, Kim HK, Choi YS, Zo JI, Shim YM, Kang JH, Lee J, Choi YL, Han J, Hwang S, Lee HY, Lee SH	Adjuvant pembrolizumab therapy for completely resected stage I lung adenocarcinoma with micropapillary or solid histological subtypes: a single-center, single-arm, phase 2 trial.	EClinicalMedicine	doi: 10.1016/j.eclinm.2025.103282
40524516	2025 Jun	Dou Z, Wang L, Rui M, Yang Y, Zhou Y, Zhang J, Zhao Q, Wang M, Wang H, Zhang X, Cui X, Si X, Zhang L	Safety and Efficacy of the First Subcutaneous ICI, Envafolimab, in the Treatment of Advanced Lung Cancer Patients: A Real-World Study.	Thoracic cancer	doi: 10.1111/1759-7714.70101
40524159	2025 Jun 16	Gong L, Liu Y, Feng J, Xiao C, Liu C, Chen B, Chen L, Jin M, Guan Y, Gao Z, Huang W	An immune activator encapsulating PD-L1 siRNA for augmented immune checkpoint blockade immunotherapy through Zn(2+) overload triggered pyroptosis.	Journal of nanobiotechnology	doi: 10.1186/s12951-025-03521-9
40523887	2025 Jun 16	Huang D, Xu M, Wang H, Zhao Y, Zhang Z, Yu M, Zhou M, Pan J, Zeng H, Yu Z, Yu Q, Wu M, Xu W, Zhou B, Zhang B, Li H, Guo L, Xie P	SIRPα blockade therapy potentiates immunotherapy by inhibiting PD-L1(+) myeloid cells in hepatocellular carcinoma.	Cell death & disease	doi: 10.1038/s41419-025-07779-7
40523480	2025 Jun 14	Shi X, Zhao X, He Y, Zhang L, Zheng X, Qin X, Li K, Li J, Wang Y, Dai L, Li X	Posttranslational remodeling micelle reverses cell-surface and exosomal PD-L1 immunosuppression in tumors resistant to PD-L1 antibody therapy.	Journal of controlled release : official journal of the Controlled Release Society	doi: 10.1016/j.jconrel.2025.113961
40523369	2025 Jun 13	Agarwal N, Azad AA, Carles J, Matsubara N, Oudard S, Saad F, Merseburger AS, Soares A, McGregor BA, Zurawski B, Tsiatas M, North S, Bondarenko I, Alfie M, Bournakis E, Antonuzzo L, Evilevitch L, Simmons A, Wang F, Ferraldeschi R, Nandoskar P, Pal SK	Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial.	The Lancet. Oncology	pii: S1470-2045(25)00209-8. doi: 10.1016/S1470-2045(25)00209-8
40523368	2025 Jun 13	Zhou C, Wang Z, Sun M, Cao L, Ma Z, Wu R, Yu Y, Yao W, Sun S, Chen J, Zhuang W, Cui J, Chen X, Lu Y, Shen H, Hu C, Liu J, Liu Y, Wang M, Li X, Sun P, Shu Y, Zhou J, Li J, Gu K, Wang C, Zhao H, Zhang Y, Liu C, Yang H, Zhang X, Ma R, Li L, Liang L, Li M, Wang J, Wang Q, Wang B, Dai H, Shi Q, Yang J	Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial.	The Lancet. Oncology	pii: S1470-2045(25)00198-6. doi: 10.1016/S1470-2045(25)00198-6
40523335	2025 Jun 6	Tao C, Wen M, Qiu P, Niu S, Wang X, Yu N, Li M, Chen Z, Pan L	Integrating magnetic field-initiated thermal-thermodynamic therapy and immune checkpoint blockade to boost antitumor immunotherapy.	Journal of colloid and interface science	doi: 10.1016/j.jcis.2025.138113
40523200	2025 Jun 16	Lee CY, Dean I, Richoz N, Li Z, Kennedy BC, Vettore LA, Samarakoon Y, Gilroy KL, Hasegawa T, Carlesso G, Hammond SA, Dovedi SJ, Sansom OJ, Tuong ZK, Halim TY, Withers DR, Clatworthy MR	In vivo labelling resolves distinct temporal, spatial, and functional properties of tumour macrophages, and identifies subset-specific effects of PD-L1 blockade.	Cancer immunology research	doi: 10.1158/2326-6066.CIR-24-1233
40522298	2025 Jun 16	Michael M, Wong R, Gill S, Strickland AH, Pavlakis N, Shapiro JD, Link E, Farrell M, Ngan SY, Tie J, Heriot AG, Goldstein D, Mitchell C, Roth S, Wilson K, Mui M, Ramsay RG, Segelov E	The Ave-Rec trial: Phase II trial of PDL1/PD-1 blockade with Avelumab post Chemoradiotherapy for locally advanced resectable T3B-4/N1-2 Rectal cancer.	Clinical cancer research : an official journal of the American Association for Cancer Research	doi: 10.1158/1078-0432.CCR-25-0705
40521348	2025 Jun	Gaillard SL, Broadwater G, Berchuck A, Andrews WS, Havrilesky LJ, Davidson BA, Previs RA, Starr MD, Yi JS, Nixon AB, Neff JL, Conejo-Garcia JR, Secord AA	A pilot study investigating the effect of pembrolizumab on the tumoral immunoprofile of newly diagnosed mullerian cancers.	Gynecologic oncology reports	doi: 10.1016/j.gore.2025.101770
40521268	2025 May 7	Eskazan T, Saribas S, Kocazeybek B	Prognostic value of the triglyceride-glucose index in gastric cancer.	World journal of gastroenterology	doi: 10.3748/wjg.v31.i17.104651
40521255	2025 May 7	Eskazan T, Saribas S, Kocazeybek B	Prognostic value of the triglyceride-glucose index in gastric cancer.	World journal of gastroenterology	doi: 10.3748/wjg.v31.i17.104651
40521219	2025 Jul	Ali SH, Ali H, Shafi M, Malik A	Breaking barriers: exploring blood-brain barrier crossing mechanisms with nanomedicine for effective glioma treatment.	3 Biotech	doi: 10.1007/s13205-025-04378-3
40521010	2025	Chen TF, Li ZJ, Zhao HS, Yang R	Feasibility and Safety of Anlotinib Combined with Immune Checkpoint Inhibitors in Patients with Previously Immunotherapy-Treated Extensive-Stage Small Cell Lung Cancer: A Retrospective Exploratory Study.	Drug design, development and therapy	doi: 10.2147/DDDT.S525481
40520871	2025	Li Z, Shi J, Wu X, Yan S, Gao Z, Liu Y	Gut microbiota is associated with the disease characteristics of patients with newly diagnosed diffuse large B-cell lymphoma.	American journal of cancer research	doi: 10.62347/DIMG6893
40520853	2025	Yang CJ, Chuang CH, Chen YW, Huang CT, Wang PH, Zhen YY, Shah SA, Sehar M, Chuang PK	The complex interplay of TROP2 and PD-L1 in immune regulation and drug resistance in lung cancer.	American journal of cancer research	doi: 10.62347/NHFJ1535
40520531	2025	Wu J, Zhang C, Cao Q, Xuan W, Huai X, Zhou J, Tian J	Bibliometric analysis of global research on PD-L1/PD-1 pathway and neurodegenerative diseases over the last two decades (2004-2023).	Frontiers in aging neuroscience	doi: 10.3389/fnagi.2025.1570428
40520331	2025 Aug	Reith FH, Jarosch A, Albrecht JP, Ghoreschi F, Flörcken A, Dörr A, Roohani S, Schäfer FM, Öllinger R, Märdian S, Tielking K, Bischoff P, Frühauf N, Brandes F, Horst D, Sers C, Kainmüller D	PD-L1 expression assessment in Angiosarcoma improves with artificial intelligence support.	Journal of pathology informatics	doi: 10.1016/j.jpi.2025.100447
40520158	2025	Guo Y, Han S, Guo Q, Zhai J, Ren X, Li S, Duan J	Real-world analysis of immunochemotherapy in recurrent small-cell lung cancer: opportunities for second-line approaches.	Frontiers in pharmacology	doi: 10.3389/fphar.2025.1591643
40520113	2025 Jun 20	He J, Liu H, Dong Y, Hu C, Liang H, Shou D, Cao D, Du Y, Shao X, Lu Y, Wang H, Tuo C, Deng J, Zhang R, Wang X, Li B, Zhong N, Liu Y, Zhong Y, Gong W	Evolution of HER2 expression after neoadjuvant therapy in locally advanced gastric cancer.	iScience	doi: 10.1016/j.isci.2025.112710
40519936	2025	Yao J, Sun Q, Wu H, Zhao X, Yang P, Wang X, Wang X, Gu M, Li J, Zheng Y, Gong Z, Zhang D, Wang W	Decoding the molecular landscape: HER2 and PD-L1 in advanced gastric cancer.	Frontiers in immunology	doi: 10.3389/fimmu.2025.1567308
40519935	2025	Wang Z, Sun C, Wang P, Lin S, Wu X, Gu Y	Pan-cancer analysis of TMED2: unraveling potential immune characteristics and prognostic value in cancer therapy.	Frontiers in immunology	doi: 10.3389/fimmu.2025.1578627
40519906	2025	Wang Y, Zhang Z, Xie T, Liu Y, Zhang C, Li H, Feng R, Huang B, Liu Q, Wang N, Xing X, Han Y, Li X, Wang R, He J, Peng Z	Baseline profile peripheral Tfh cells predict immune-related adverse events in immune checkpoint inhibitor therapy of gastrointestinal cancer.	Frontiers in immunology	doi: 10.3389/fimmu.2025.1559275
40519900	2025	Ma H, Zhang S, Jiao P, Ding H, Wang F, Zhao Y, Wu J, Guo Z	Serum IL-6 predicts immunotherapy-related adverse and outcome in advanced gastric and esophageal cancer patients with Anti-PD-1 treatment.	Frontiers in immunology	doi: 10.3389/fimmu.2025.1553882
40518873	2025 Jun	Thomsen C, Birkelund S, Røge R	Immunohistochemical Profiling of Interferon-Stimulated Genes in Histopathological Specimens: A Potential Screening Approach for Viral Infections.	APMIS : acta pathologica, microbiologica, et immunologica Scandinavica	doi: 10.1111/apm.70034
40518811	2025 Jan-Dec	Xia X, Chen S, Huang C, Ye Y, Shen Y, Wang L	A new Score for Predicting Immune Checkpoint Inhibitor-Associated Thrombosis in Cancer Patients.	Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis	doi: 10.1177/10760296251351020
40518810	2025 Jun 16	Huang H, Peng H, He Y, Chen Y, Ye Q, Jin S, Yin N, Yang Q, Gao Y, Yang L, Bu X, Wu W, Feng M, Guo L	Self-Driving and Detachable Lab-Microrobots Tailor Drug Delivery for Closed-Loop Stimulation of the Antitumor Immune Cycle.	ACS nano	doi: 10.1021/acsnano.4c15868
40518797	2025 Jun 16	Yang Z, Yang P, Xu J, Yang X, Zhou J, He H, Li L, Ren Y, Chen M, Xiao Y, Chen J	Discovery and Crystallography Study of Novel Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment.	Journal of medicinal chemistry	doi: 10.1021/acs.jmedchem.5c00344
40518504	2025 Jun 15	Su M, Duan H, Gu Y, Zhao J	Hypoxia-related signatures predicts survival, immunosuppression and PARP inhibitor resistance in HCC.	Discover oncology	doi: 10.1007/s12672-025-02923-3
40518311	2025 Jun 13	Hidaka R, Hiromatsu Y, Tatsumoto N, Fukuyama T, Sagara Y, Uchida A, Tamai H, Tojikubo M, Akehi Y, Kawasaki E, Nakamura H	Development of Thyrotoxicosis With Positive TSH Receptor Antibody and Transition to Hypothyroidism in a Patient With Unresectable Hepatocellular Carcinoma During Combined Atezolizumab and Bevacizumab Therapy: A Case Report and Review of the Literature.	The Kurume medical journal	doi: 10.2739/kurumemedj.MS7134008
40518290	2025 Jun 15	Dadey RE, Li R, Griner J, Chen J, Singh A, Isett B, Newman S, Augustin R, Li A, Manning JA, Monga SP, Singhi A, Geller DAA, Krieg C, Zervantonakis IK, Luke JJ, Bao R	Multiomics identifies tumor-intrinsic SREBP1 driving immune exclusion in hepatocellular carcinoma.	Journal for immunotherapy of cancer	pii: e011537. doi: 10.1136/jitc-2025-011537
40518088	2025 Jun 13	Zhu Y, Zhang J, Zhao X, Guo M, Chen C, Zhou Y, Xu L	MicroRNA-7 as a Multifaceted Regulator of Tumor Glycolytic Metabolism: Mechanistic Insights and Therapeutic Perspectives.	Pharmacological research	doi: 10.1016/j.phrs.2025.107822
40517973	2025 Jun 13	Li L, Huang Y, Xue R, Li G, Li L, Liang L, Lai K, Huang X, Qin Y, Zheng Y	T Cell-Mediated Mechanisms of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors.	Critical reviews in oncology/hematology	doi: 10.1016/j.critrevonc.2025.104808
40517176	2025 Jun 14	Heimer MM, Cimic A, Kloiber-Langhorst S, Antons MJ, Stueckl J, Hirner-Eppeneder H, Kunz WG, Dietrich O, Ricke J, Herr FL, Cyran CC	Quantitative response assessment of combined immunotherapy in a murine melanoma model using multiparametric MRI.	European radiology experimental	doi: 10.1186/s41747-025-00597-8
40517100	2025 Jun 6	Wu Y, Lu WM, Cui QR, Zhou J, Lu GD	Metabolic Regulation of cGAS-STING Signaling in the Tumor Microenvironment: Dual Immune Roles and Therapeutic Implications.	Cytokine & growth factor reviews	pii: S1359-6101(25)00074-7. doi: 10.1016/j.cytogfr.2025.06.002
40516913	2025 Jun 12	Hushmandi K, Farahani N, Einollahi B, Salimimoghadam S, Alimohammadi M, Liang L, Liu L, Sethi G	Deciphering molecular pathways in urological cancers: a gateway to precision therapeutics.	Journal of advanced research	pii: S2090-1232(25)00395-9. doi: 10.1016/j.jare.2025.06.009
40516842	2025 Jun 12	Sun M, Ni C, Li A, Liu J, Guo H, Xu F, Li K, Cao X, Shi X, Guo R	A Biomimetic Nanoplatform Mediates Hypoxia-Adenosine Axis Disruption and PD-L1 Knockout for Enhanced MRI-Guided Chemodynamic-Immunotherapy.	Acta biomaterialia	pii: S1742-7061(25)00435-0. doi: 10.1016/j.actbio.2025.06.021
40516668	2025 Jun 12	Tan J, Zhu D, Li G, Hu H, Lai Z, Li Z	A novel theranostic system of PD-L1-Aptamer-functionalized fluorescent silica nanoparticles for triple-negative breast cancer.	Nanomedicine : nanotechnology, biology, and medicine	doi: 10.1016/j.nano.2025.102834
40516574	2025 Jun 12	Kong M, Qiu L	Coordinated modulation of glucose metabolism and immunity via metal-drug nanovesicles for hepatocellular carcinoma therapy.	Journal of controlled release : official journal of the Controlled Release Society	doi: 10.1016/j.jconrel.2025.113957
40516320	2025 Jun 7	Grünwald V, Bex A, Rottey S, Suárez C, Procopio G, Velasco G, Melichar B, Bedke J, Pickering L, Fontes-Sousa M, Schmidinger M, Bamias A, Gross-Goupil M, Porta C, Barthélémy P, Escudier B, Albiges L	Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: Insights from a European delphi study.	European journal of cancer (Oxford, England : 1990)	doi: 10.1016/j.ejca.2025.115569
40515614	2025 Jun 14	Akbari B, Hasan MM, Islam SM	Advances in targeted therapy for triple-negative breast cancer: a review of key antigens and recent advances.	Journal of drug targeting	doi: 10.1080/1061186X.2025.2520306
40515573	2025 Jun 15	Belani N, Donnelly A, Spira A	An evaluation of datopotamab deruxtecan for the treatment of non-small cell lung cancer.	Expert opinion on biological therapy	doi: 10.1080/14712598.2025.2519532
40515479	2025 Jun 4	Sullivan RJ, Yeku OO, Teoh D, Gupta S, Matei D, Laino AS, Sun J, Zhu L, Van L, Pascarella S, Zacharek SJ, Do KT, Jimeno A	First-in-human phase I/II, open-label study of mRNA-2416 alone or combined with durvalumab in patients with advanced solid tumors and ovarian cancer.	The oncologist	doi: 10.1093/oncolo/oyaf115
40514707	2025 Jun 13	Petroková H, Mierzwicka JM, Chakraborty P, Rašková Kafková L, Vaculová J, Škarda J, Fischer O, Kosztyu P, Kuchař M, Raška M, Malý P	Myomedin variants developed for in vitro PD-L1 diagnostics in tissue samples of non-small cell lung carcinoma patients.	Journal of translational medicine	doi: 10.1186/s12967-025-06699-6
40514706	2025 Jun 13	Wang J, Zhu G, Guo J, Teng G	Hepatic artery infusion chemotherapy plus an immune checkpoint inhibitor and lenvatinib for the treatment of biliary tract carcinoma.	World journal of surgical oncology	doi: 10.1186/s12957-025-03882-3
40514659	2025 Jun 13	Hsiao CH, Lin YW, Liu CH, Chen YT, Nguyen HT, Chuang AE	Nano-orchestrated magnetotactic-like navigation for electromagnetic theranostics and immune enhancement via photoautotrophic oxygenation, mild hyperthermia, and ferroptosis.	Journal of nanobiotechnology	doi: 10.1186/s12951-025-03488-7
40514658	2025 Jun 13	Jin X, Wuyun T, Zhang Y, Wang X, Zhao L	Overcoming acquired immunotherapy resistance in non-small cell lung cancer using ginsenoside Rb1-loaded, peptide-enhanced exosome delivery systems.	Journal of nanobiotechnology	doi: 10.1186/s12951-025-03456-1
40514550	2025 Jun 13	Xiao D, Dong J, Xie F, Feng X, Wang J, Xu X, Tang B, Sun C, Wang Y, Zhong W, Deng H, Zhou X, Li S	Polyvalent folate receptor-targeting chimeras for degradation of membrane proteins.	Nature chemical biology	doi: 10.1038/s41589-025-01924-1
40514360	2025 Jun 13	Lee JY, Kim KJ, Park W, Seo J, Kang M, Jung EH, Kim SA, Suh KJ, Kim JW, Kim SH, Lee JO, Kim JW, Kim YJ, Lee KW, Kim JH, Bang SM, Kim TM, Paik JH	Early growth response 1 as a key regulator of PD-L1 expression and immune evasion in extranodal NK/T-cell lymphoma.	Blood cancer journal	doi: 10.1038/s41408-025-01313-w
40514069	2025 Jun 12	Zhang Y, Yu F, Ouyang J, Liu P, Dai Y, Wang Y, Yi H, Wang S, Liu D, Song K, Pei W, Hong Z, Zhang W, Huang W, Zhou G, Cao S, McLeod H, Peng C, Chen L, He Y	ADRB2 inhibition suppresses cancer immune evasion by regulating tumor SOX10-PD-L1 axis and T cell function.	Journal for immunotherapy of cancer	doi: 10.1136/jitc-2025-011611
40514068	2025 Jun 13	Chen S, Zhao Y, Cao M, Peng W, Huang H, Yang Y, Liang J, Chen W, Bai S, Zhou Q, Jiang J, Gu Y, Wang R, Cheng B	Anti-CTGF/PD-1 bispecific antibody Y126S restrains desmoplastic and immunosuppressive microenvironment in pancreatic cancer.	Journal for immunotherapy of cancer	pii: e012144. doi: 10.1136/jitc-2025-012144
40513811	2025 Jun 11	Saeed SH, Sinnamon AJ, Fontaine JP, Mehta RJ, Baldonado JJ, Pena LR, Pereira AAL, Hoffe SE, Frakes JM, Pimiento JM	Survival after Esophagectomy for Metastatic Esophageal Cancer: Should the Role of Surgery be Reconsidered?	Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract	doi: 10.1016/j.gassur.2025.102118
40513669	2025 Jun 11	Henrich EM, McHugh KJ	Advanced biomaterials for the targeted delivery of immune checkpoint inhibitors to solid tumors.	Journal of controlled release : official journal of the Controlled Release Society	doi: 10.1016/j.jconrel.2025.113951
40513524	2025 Jun 12	Yu B, Qi C, Liu Z, Ma N, Tian C, Wang Y, Li C, Li Z	Spatial heterogeneity of PD-L1 expression influence its assessment in esophageal squamous cell carcinoma.	Translational oncology	doi: 10.1016/j.tranon.2025.102442
40513286	2025 Jun 7	Jiménez-Labaig P, Mohamed F, Tan NJI, Sanna I, El Bairi K, Khan SZ, Akhade A, Amaral T, Trapani D, Patel A, Harrington KJ	Expanding access to cancer immunotherapy: A systematic review of low-dose PD-(L)1 inhibitor strategies.	European journal of cancer (Oxford, England : 1990)	doi: 10.1016/j.ejca.2025.115564
40513285	2025 Jun 3	Lipson EJ, Stephen Hodi F, Tawbi H, Schadendorf D, Ascierto PA, Matamala L, Gutierrez EC, Rutkowski P, Gogas HJ, Lao CD, Menezes JJ, Dalle S, Arance A, Gaudy-Marqueste C, Chen B, Jackson W, Mukherjee S, Dolfi S, Long GV	Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update.	European journal of cancer (Oxford, England : 1990)	doi: 10.1016/j.ejca.2025.115547
40513139	2025 Jun 12	Sato S, Rhodes SL, Aoki Y, Nakayama I, Hashimoto T, Hawkins J, Yanes RE, Chang CH, Nakamura Y, Kawazoe A, Mishima S, Kotani D, Kuboki Y, Bando H, Kojima T, Yoshino S, Reading S, Honeycutt H, Finger E, Endo I, Sakamoto N, Kuwata T, Yoshino T, Shitara K	Clinical characterization of FGFR2b expression in patients with advanced gastric or gastroesophageal junction adenocarcinoma.	ESMO open	doi: 10.1016/j.esmoop.2025.105322
40512406	2025 Jun 13	Yang Z, Zhong D, Hu X, Chen W, Liao Y, He X	NFATC2/SERPINE1/JAK3/STAT3 signaling feedback loop in gastric cancer: immune evasion and anti-PD-1 resistance.	Cell biology and toxicology	doi: 10.1007/s10565-025-10050-6
40512241	2025 Jun 13	Tang LQ, Liu SL, Yang MH, Wang HC, Zhou YJ, Yang KY, Li Q, Hui M, Chen XZ, Leu YS, Chen LT, Liu LT, Guo SS, Chen QY, Wang S, Zhu HQ, Shen HG, Wang Y, Guo Y, Mai HQ	GFH018 and toripalimab combination therapy for previously treated recurrent or metastatic nasopharyngeal carcinoma: Results from a phase 1b/2 study.	Clinical cancer research : an official journal of the American Association for Cancer Research	doi: 10.1158/1078-0432.CCR-25-0085
40512213	2025 Jun 13	Hong Y, Chen S, Jiang X, Zhang J, Liang X, Yao J, Gao S, Hua C	Exosomes as immunomodulators in autoimmune inflammation: implications for primary Sjögren's disease.	Inflammation research : official journal of the European Histamine Research Society ... [et al.]	doi: 10.1007/s00011-025-02053-0
40512146	2025 Jun 13	Li S, Shapiro JW, Shah H, Higgs EF, Xie L, Li Y, Zha Y, Trujillo J, Cabanov A, Jones TA, Flood B, Hatogai K, Tonea R, Kline J, Gajewski TF	Tumor cell-intrinsic Decr2 regulates ferroptosis and immunotherapy efficacy.	Cancer immunology research	doi: 10.1158/2326-6066.CIR-24-0519
40512079	2025 Jun 13	Tiburcio PDB, Desai K, Warne A, Nabbi A, Zhou S, Reiff SD, Campbell ME, Amatruda JF, Chen KS	PD-L1 Expression is Mediated by microRNA Processing, Wnt/β-Catenin Signaling, and Chemotherapy in Wilms Tumor.	Pediatric blood & cancer	doi: 10.1002/pbc.31852
40511826	2025 Jun 12	Li C, Zhu H, Lin Q, Chen W, Huang X, Wang D	Determination of PD-L1 Expression in Circulating Tumor Cells of Hypopharyngeal and Laryngeal Cancers and Correlation with Tissue Detection.	Anti-cancer agents in medicinal chemistry	doi: 10.2174/0118715206340244250605061005
40511536	2025 Jul	Park AY, Kim JH, Lee S, Kim HS, Kim HK, Lee HB, Han W	Impact of PD‑L1 upregulation on immune checkpoint inhibitor efficacy in triple‑negative breast cancer using a 4T1 murine model.	International journal of oncology	pii: 54. doi: 10.3892/ijo.2025.5760
40510923	2025 Jun	Tay-Teo K, Trapani D, Sengar M, Aziz Z, Meheus F, Ilbawi A, de Vries EGE, Moja L	Modelling the potential financial impacts of expanding access to immune checkpoint inhibitors as monotherapy for treating advanced non-small cell lung cancer.	EClinicalMedicine	doi: 10.1016/j.eclinm.2025.103261
40510401	2025 Jun	Pixberg C, Maurer C, Smetanay K, Straßl L, Hlevnjak M, Zapatka M, Wagner CV, Yazdanparast H, Kurzawa J, Erben V, Feng F, Hong C, Hübschmann D, Buschhorn L, Suppelna JP, Michel L, Heublein S, Fremd C, Zivanovic O, Sinn P, Stenzinger A, Haidinger R, Schumacher-Wulf E, Ditsch N, Loibl S, Fröhling S, Link T, Wimberger P, Blohmer JU, Huebner H, Fasching PA, Janni W, Schlenk RF, Thewes V, Lichter P, Schneeweiss A	COGNITION-GUIDE - Genomics-Guided Targeted Post-Neoadjuvant Therapy in Patients with Early Breast Cancer: Study Design of a Multicenter, Open-Label, Umbrella Phase II Study.	Geburtshilfe und Frauenheilkunde	doi: 10.1055/a-2557-1876
40510364	2025	Yao Z, Li G, Pan D, Pei Z, Fang Y, Liu H, Han Z	Roles and functions of tumor-infiltrating lymphocytes and tertiary lymphoid structures in gastric cancer progression.	Frontiers in immunology	doi: 10.3389/fimmu.2025.1595070
40510356	2025	Hu M, Yin R, Deng K, Xu N	Drug repurposing of fostamatinib against cancer via potential cytotoxicity and immune checkpoint regulation.	Frontiers in immunology	doi: 10.3389/fimmu.2025.1602189
40510355	2025	Yang F, Mao Y, Huang H, Luo W, Liu L, Chen W	The efficacy and safety of regorafenib/fruquintinib combined with PD-1/PD-L1 for metastatic colorectal cancer: a meta-analysis based on single-arm studies.	Frontiers in immunology	doi: 10.3389/fimmu.2025.1579293
40510347	2025	Liu Y, Qin D, Fu J	T lymphocyte heterogeneity in NSCLC: implications for biomarker development and therapeutic innovation.	Frontiers in immunology	doi: 10.3389/fimmu.2025.1604310
40510346	2025	Zimmer YN, Hanke B, Neyazi B, Rashidi A, Schaufler A, Dumitru CA, Ignatov A, Mawrin C, Sandalcioglu IE, Stein KP	The landscape and clinical impact of tumor-associated macrophages and PD-L1 in primary breast cancers and their brain metastases.	Frontiers in immunology	doi: 10.3389/fimmu.2025.1598293
40510156	2025	Chen C, Chen J, Zhang Y, Zhang Q, Shi H	Senescence-associated secretory phenotype in lung cancer: remodeling the tumor microenvironment for metastasis and immune suppression.	Frontiers in oncology	doi: 10.3389/fonc.2025.1605085
40509605	2025 Jun 12	Huang Y, He S, Xu J, Zou T, Liu J, Huang C, Chen Y, Liu H, Lei A, Wei H, Yu CY	Biomimetic Delivery of Cisplatin for Efficient Immunotherapy of Gasdermin E-Positive Hepatocellular Carcinoma via a Pt Concentration-Dependent Minimalist Pyroptosis Strategy.	Advanced healthcare materials	doi: 10.1002/adhm.202500766
40509568	2025 Jun 12	Wang H, Yi X, Qu D, Wang X, Wang H, Zhang H, Yang Y, Gao T, Guo W, Li C	Tumorous cholesterol biosynthesis curtails anti-tumor immunity by preventing MTOR-TFEB-mediated lysosomal degradation of CD274/PD-L1.	Autophagy	doi: 10.1080/15548627.2025.2519066
40508202	2025 Jun 4	Morchón-Araujo D, Catani G, Mirallas O, Pretelli G, Sánchez-Pérez V, Vieito M, Braña I, Pujol-Borrell R, Garralda E, Hernando-Calvo A	Emerging Immunotherapy Targets in Early Drug Development.	International journal of molecular sciences	doi: 10.3390/ijms26115394
40508140	2025 Jun 1	Cao G, Memida T, Huang S, Dalir Abdolahinia E, Ruiz S, Hassantash S, Ari J, Shindo S, Lin J, Kawai T, Han X	Pro-Resolving Macrophage-Induced IL-35(+) but Not TGF-β1(+) Regulatory B Cell Activation Requires the PD-L1/PD-1 Pathway.	International journal of molecular sciences	doi: 10.3390/ijms26115332
40507905	2025 May 26	Liu P, Chen Y	Integrative Analysis of EPHX4 as a Novel Prognostic and Diagnostic Biomarker in Lung Adenocarcinoma.	International journal of molecular sciences	doi: 10.3390/ijms26115095
40507370	2025 Jun 5	Pourakbar N, Motamedi A, Pashapour M, Sharifi ME, Sharabiani SS, Fazlollahi A, Abdollahi H, Rahmim A, Rezaei S	Effectiveness of Artificial Intelligence Models in Predicting Lung Cancer Recurrence: A Gene Biomarker-Driven Review.	Cancers	doi: 10.3390/cancers17111892
40507271	2025 May 27	Moiseenko F, Radulovic M, Tsvetkova N, Chernobrivceva V, Gabina A, Oganesian A, Makarkina M, Elsakova E, Krasavina M, Barsova D, Artemeva E, Khenshtein V, Levchenko N, Chubenko V, Egorenkov V, Volkov N, Bogdanov A, Moiseyenko V	Baseline Radiomics as a Prognostic Tool for Clinical Benefit from Immune Checkpoint Inhibition in Inoperable NSCLC Without Activating Mutations.	Cancers	doi: 10.3390/cancers17111790
40507250	2025 May 25	Voiculescu VM, Popescu AI, Costache M	Immunohistochemistry for Skin Cancers: New Insights into Diagnosis and Treatment of Melanoma.	Cancers	doi: 10.3390/cancers17111769
40507249	2025 May 25	Mun HS, Kim SH, Lee J, Park SJ, Lee A, Kang J, Park WC, Bae SY, Choi BO, Hong JH, Oh SN, Shin K	Skeletal Muscle Density as a Predictive Marker for Pathologic Complete Response in Triple-Negative Breast Cancer Treated with Neoadjuvant Chemoimmunotherapy.	Cancers	doi: 10.3390/cancers17111768
40507229	2025 May 23	Mani M, Park JW, Martin TFJ	Regulatory Mechanisms and Therapeutic Targeting of PD-L1 Trafficking and Stability in Cancer Immunotherapy.	Cancers	doi: 10.3390/cancers17111747
40506719	2025 Jun 12	Dai L, Huang L, Li L, Tang L, Shi Y, Han X	Unraveling the role of HDAC3 as an immunotherapy prognostic biomarker and therapeutic target in advanced non-small cell lung cancer.	Respiratory research	doi: 10.1186/s12931-025-03275-w
40506611	2025 Jun 12	Liang H, Liu X, Guo W, Xiong W, Ren D, Liu W	OTUD1 downregulates PD-L1 expression by deubiquitinating STAT3 and promotes the immune response in CcRCC.	Cellular oncology (Dordrecht, Netherlands)	doi: 10.1007/s13402-025-01079-0
40506028	2025 Jun 9	Jang EB, So KA, Kim WY, Lim SD, Kim TJ, Bang H, Kim WS	Programmed Death-Ligand 1 Expression Across Multiple Assays in Ovarian Cancer: A Comparative Analysis.	Cancer research and treatment	doi: 10.4143/crt.2025.202
40505815	2025 Jun 10	Elnour R, Hindenes IH, Færevaag M, Moss Kolseth IB, Vestrheim Thomsen LC, Johannessen AC, Costea DE, Bjørge L, Dongre HN	Prognostic value of an integrated human papillomavirus and immunoscore model to predict survival in vulva squamous cell carcinoma.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	doi: 10.1016/j.modpat.2025.100809
40505659	2025 Jun 11	Xing YL, Panovska D, Park JW, Grossauer S, Koeck K, Bui B, Nasajpour E, Nirschl JJ, Feng ZP, Cheung P, Habib P, Wei R, Wang J, Thomason W, Monje M, Xiu J, Beck A, Weber KJ, Harter PN, Lim M, Mahaney KB, Prolo LM, Grant GA, Ji X, Walsh KM, Mulcahy Levy JM, Hambardzumyan D, Petritsch CK	BRAF/MEK inhibition induces cell state transitions boosting immune checkpoint sensitivity in BRAF(V600E)-mutant glioma.	Cell reports. Medicine	doi: 10.1016/j.xcrm.2025.102183
40505642	2025 Jun 12	Wang DP, Zhou HY, Zhang Y, Xue L, Wu ZB	Advances in drug treatments for male patients with prolactinomas.	Neuroendocrinology	doi: 10.1159/000546443
40505466	2025 Jun 3	Ji A, Yang P, Ma B, Li J, Yu Y, Zhang X, Chen P, Yao H, Shi L, Hu H, Gao S, Cheng H	Photothermal-responsive curcumin-loaded copper-based nanocomposites for targeted drug release and combined immunotherapy.	Journal of colloid and interface science	doi: 10.1016/j.jcis.2025.138042
40505269	2025 Jun 11	Liu Y, Jiang X, Jing D, Lin Y, Gao R, Zhao Q, Da H, Ren Y, Cao Q, Liu N, Han X, Du J, Gao X	ACSL4 knockdown inhibits colorectal cancer progression through stimulating anti-tumor immunity.	Neoplasia (New York, N.Y.)	doi: 10.1016/j.neo.2025.101194
40505138	2025 Jun 12	Jiang T, Ge M, Liang T, Cai L, Yu X, Xie F, Wang L, Zhang J, Zhou F, Lu Q, Lan J	Discovery of a Selective, Novel TGF-βR1 Inhibitor GFH018 for the Treatment of Solid Tumors.	Journal of medicinal chemistry	doi: 10.1021/acs.jmedchem.5c00121
40504869	2025	Manzoor H, Khan MU, Khan S, Shah M, Shabbir CA, Alkhtani HM	Linalool-based silver nanoconjugates as potential therapeutics for glioblastoma: in silico and in vitro insights.	PloS one	doi: 10.1371/journal.pone.0325281
40504774	2025 Jun	Sun Z, Ma X, Li J, Fan L, Zhao C, Yin S, Hu H	δ-Tocotrienol Potentiates Breast and Prostate Cancer Cells to Paclitaxel via Suppressing PD-L1-Mediated Cancer-Promoting Signaling.	Chemical biology & drug design	doi: 10.1111/cbdd.70143
40504295	2025 Jun 12	Zhang Q, Yang C, Zhou B, Gao X, Zhong C, Shi Y, Cao H, Zhu M	KLF4 mediates the contradictory effects of phenylethyl isothiocyanate in gastric cancer intervention.	Medical oncology (Northwood, London, England)	doi: 10.1007/s12032-025-02795-1
40503775	2025 Jun 12	Zhanga Y, Wang X, Li J, Zhang P, Hu H	Global clinical trial landscape and therapeutic trends in bladder cancer: a systematic analysis.	International journal of surgery (London, England)	doi: 10.1097/JS9.0000000000002662
40503548	2025	Liu J, Xie M, Shen J, Yao J, Lin X, Bao X, Zhang X, Liang Y, Yang Y, Jiang G, Diao X, Han W, Du H, Xue X, Wu J	Advances in Multimodal Imaging Techniques for Evaluating and Predicting the Efficacy of Immunotherapy for NSCLC.	Cancer management and research	doi: 10.2147/CMAR.S522136
40503235	2025	Kondo R, Kondo K, Nabeshima K, Nishikimi A, Ishida Y, Shigeoka T, Dijkstra JM	PD-1 is conserved from sharks to humans: new insights into PD-1, PD-L1, PD-L2, and SHP-2 evolution.	Frontiers in immunology	doi: 10.3389/fimmu.2025.1573492
40503034	2025 Aug	Wang Y, Chen X, Fu Z, Wang H, Yu W	Managing severe dermatitis and grade 4 pneumonitis in a patient with non-small-cell lung cancer following pembrolizumab treatment: A case report.	Oncology letters	doi: 10.3892/ol.2025.15126
40502681	2025 Jun 20	Zhang Y, Yin K, Ma R, Sun Y, Wang L, Yin D	Complex regulatory network of programmed death-ligand 1 in cancer: Cancer immunomodulation from molecular mechanisms to clinical applications.	iScience	doi: 10.1016/j.isci.2025.112615
40502578	2025 Jun 6	Zhu X, Yu Y, Li Y, Wang P, Li Y, McCabe C, Chen S, Langenfeld HE, Hanson AC, Sharp BE, Woltzen A, Crowson CS, Markovic SN, Davis JM, Dong H, Thanarajasingam U, Zeng H	Inflammatory arthritis immune related adverse events represent a unique autoimmune disease entity primarily driven by T cells, but likely not autoantibodies.	medRxiv : the preprint server for health sciences	pii: 2025.06.06.25328991. doi: 10.1101/2025.06.06.25328991
40502306	2025	R Choo J, Jeraj SN, Sundar R, Yong WP, Lee M, Huang Y, Asokumaran Y, Chan GHJ, Ngoi NYL, Wong ALA, Soo RA, Chee CE, Lim JSJ, Goh BC, Lee SC, Tan DSP	NEXUS: a phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies.	Therapeutic advances in medical oncology	doi: 10.1177/17588359251339930
40501860	2025 Jun 6	Haist M, Matusiak M, Tan Y, Zimmer S, Stege H, Kempchen TN, Mitschke S, Chu P, Weidenthaler-Barth B, Barlow GL, Rogall F, Delgado Gonzalez A, Baertsch MA, Albertini S, Gariglio M, Borgogna C, Goltsev Y, Grabbe S, Hickey JW, Nolan GP	Spatially organized inflammatory myeloid-CD8 (+) T cell aggregates linked to Merkel-cell Polyomavirus driven Reorganization of the Tumor Microenvironment.	bioRxiv : the preprint server for biology	pii: 2025.06.06.657162. doi: 10.1101/2025.06.06.657162
40501604	2025 May 28	Sadanaga T, Jeong HS, Cortez R, Lee JH, Kamle S, Ma B, Shin SJ, Elias JA, Lee CG	Kasugamycin inhibits melanoma lung metastasis and regulates CHI3L1-driven M2-like tumor-associated macrophage differentiation.	bioRxiv : the preprint server for biology	pii: 2025.05.26.654629. doi: 10.1101/2025.05.26.654629
40500695	2025 Jun 11	Meng X, Yang X, Hong Y, Wang W, Zhang Z, Xia J, Chen Y, Zhou Y, Lu T, Song M, Shan Z, Wu T, Wu W, Shen L, Guan L, Ma M, Wang L, Luo X, Xin D, Ma Y, Jiang G, Qi Y, Jiang B, Zhang D, Hu B, Wu X, Peng Z, Wang F	Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: an exploratory multicenter, single-arm phase II clinical trial.	Molecular cancer	doi: 10.1186/s12943-025-02376-w
40500531	2025 Jun 11	Shan W, Li G, Zhang H, Zhang R, Liu J, Gao L, Li Y, Fan L, Yang C, Liu J	TAP1 promotes immune escape by activating JNK/STAT1/PD-L1 signaling in EBV-associated gastric cancer.	Molecular and cellular biochemistry	doi: 10.1007/s11010-025-05319-7
40500332	2025 Jun 11	Kimmel BR, Arora K, Chada NC, Bharti V, Kwiatkowski AJ, Finkelstein JE, Hanna A, Arner EN, Sheehy TL, Pastora LE, Yang J, Pagendarm HM, Stone PT, Hargrove-Wiley E, Taylor BC, Hubert LA, Fingleton BM, Gibson-Corley KN, May JC, McLean JA, Rathmell JC, Richmond A, Rathmell WK, Balko JM, Wilson JT	Potentiating cancer immunotherapies with modular albumin-hitchhiking nanobody-STING agonist conjugates.	Nature biomedical engineering	doi: 10.1038/s41551-025-01400-0
40500109	2025 Jun 10	Yang W, Guo Z, Ju H, Lu Y, Fei Y, Yin Y, Ren G, Yan M, Han C, Hu J	IL-4-STAT6-induced high Siglec-G/10 expression aggravates the severe immune suppressive tumor microenvironment and impedes the efficacy of immunotherapy in head and neck squamous cell carcinoma.	Journal for immunotherapy of cancer	doi: 10.1136/jitc-2025-011474
40499717	2025 May 24	Rayner CJ, Bartlett DB, Allen SK, Wooldridge T, Seymour T, Sunshine S, Hunt J, King D, Bagwan I, Sultan J, Preston SR, Frampton AE, Annels NE, Abbassi-Ghadi N	Prehabilitation during neoadjuvant chemotherapy results in an enhanced immune response in esophageal adenocarcinoma tumors: A randomized controlled trial.	Journal of sport and health science	doi: 10.1016/j.jshs.2025.101063
40499682	2025 Jun 9	Ellis AJR, Will E, Ogurtsova A, Engle LL, Taube JM, Sunshine JC	Siglec ligand immunohistochemistry reveals association with immune exclusion and survival.	Laboratory investigation; a journal of technical methods and pathology	doi: 10.1016/j.labinv.2025.104203
40499670	2025 Jun 9	Lai S, Li N, Chen S, Wang Y, Hong D, Xu W, Chen Z, Li B, Xie C	Activated CD4(+) T cells upregulate PD-L1 expression on B cells through CD40/CD40L signaling and direct contact in systemic lupus erythematosus.	Clinical immunology (Orlando, Fla.)	doi: 10.1016/j.clim.2025.110535
40499632	2025 Jun 9	Ling H, Xiao S, Lei Y, Zhou Y, Tan J, Chen X, Ma D, Liang C, Liu Q, Liu W, Zeng T	The advancement of ubiquitination regulation in apoptosis, ferroptosis, autophagy, drug resistance and treatment of cancer.	Archives of biochemistry and biophysics	doi: 10.1016/j.abb.2025.110497
40499464	2025 Jun 10	Sharma G, Baca Y, Shields AF, Prakash A, Weinberg BA, Saeed A, Goel S, Abdalla A, Oberley M, Xiu J, Hwang J, Antonarakis ES, Chiu VK, Lou E	Uncovering PD-L1 among immune cell predictive biomarkers and actionable genetic alterations in anal squamous-cell carcinomas in the era of immunotherapy.	ESMO open	doi: 10.1016/j.esmoop.2025.105315
40499462	2025 Jun 10	Robinson HR, Lakritz S, Pavlick DC, Davis SL, Lieu CH, Eule CJ, Graham LS, Spiess PE, Li R, Kamat AM, Grivas P, Jacob JM, Bratslavsky G, Basnet A, Wong KA, Lin DI, Necchi A, Ross JS, Lam ET	Squamous cell carcinoma of unknown primary (SCCUP): a genomic landscape study.	ESMO open	doi: 10.1016/j.esmoop.2025.105312
40499273	2025 Jun 6	Rutkowski PL, Klimczak A, Teterycz P, Pantaleo MA, Switaj T, Rogala P, Poleszczuk J, Nannini M, Nigro MC, Kozak K	Avelumab plus axitinib in patients with advanced gastrointestinal stromal tumor.	European journal of cancer (Oxford, England : 1990)	doi: 10.1016/j.ejca.2025.115565
40499141	2025 Jun 11	Li C, Yao J, Yang J, Zhang Y, Qiu Y, Zhu Z, Hua H	Preclinical evaluation of DB-1419, a novel bifunctional and bispecific anti-B7-H3×PD-L1 antibody-drug conjugate.	Clinical cancer research : an official journal of the American Association for Cancer Research	doi: 10.1158/1078-0432.CCR-25-0634
40499082	2025 Jun 11	Tang X, Wen Y, Zhang Z, Song X, Zhu J, Zheng M, Li J	Codelivery of Anti-PD-L1 and Indocyanine Green by a β-Cyclodextrin-Based Nanogel Carrier System for Cancer-Targeted Photothermal and Immunotherapy.	Biomacromolecules	doi: 10.1021/acs.biomac.5c00489
40498982	2025 Jun 11	Zhang W, Yang T, Jin T, Zhu T, Hao F, Fan M, Zhang Y	Enhancing Chemotherapy-Related Immune Responses via Bioorthogonal Metabolic Engineering-Driven Tumor Exosomes Elimination.	Advanced science (Weinheim, Baden-Wurttemberg, Germany)	doi: 10.1002/advs.202506409
40498401	2025 Jun 11	Du S, Li P, Liu Y, Cai B, Li G, Wang W, Yan R, Zheng X, Bai T	FOXM1 upregulation, promotes immune escape in gastric cancer through activation of Notch signaling pathway.	Molecular and cellular biochemistry	doi: 10.1007/s11010-025-05322-y
40498284	2025 Jun 11	Sun P, Qin W, Xu H, Yin H, Yang L, Zhang X, Jin X, Xu Q, Wu H, Kuai X, Jia L, Huang J, Wang Y	SPTSSA facilitates gastric cancer progression with modulating PD-L1 in immunomicroenvironment through Wnt/β-catenin pathway.	Cellular oncology (Dordrecht, Netherlands)	doi: 10.1007/s13402-025-01072-7
40498245	2025 Jun 11	Shin E, Cha YJ, Kim HM, Koo JS	PD-L1 22C3 CPS in paired primary breast cancer and lung metastasis.	Breast cancer research and treatment	doi: 10.1007/s10549-025-07757-9
40498158	2025 Jun 11	Wang Z, Xie X, Wang Z, Tang P, Chen J, Xu J, Zhang J, Xiao H, Zheng C, Jiang J, Liu Q, Lan W	Trends and hotspots in targeted therapy resistance research for renal cell carcinoma: a bibliometric and visualization analysis.	Discover oncology	doi: 10.1007/s12672-025-02772-0
40497783	2025 Jun 11	Zhang D, Li J, Liang Y, Li T, Ji M, Liu X, Li W, Chen P, Zhang J, Yang Z, Wang L, Chen H	Extracellular HSP90-Facilitated Degradation of Extracellular and Membrane Proteins by Bifunctional Small Molecules.	Journal of medicinal chemistry	doi: 10.1021/acs.jmedchem.5c00379
40497089	2025 May 21	Hu XN, Li CF, Huang SM, Nie CL, Pang R	Pescadillo ribosomal biogenesis factor 1 and programmed death-ligand 1 in gastric and head and neck squamous cell carcinoma.	World journal of gastroenterology	doi: 10.3748/wjg.v31.i19.106644
40496871	2025	Zhang L, Zhang Y, Li S, Wang Y, Yu Y, He J, Gao W	Case Report: Robust and durable response to the combination of tislelizumab and chemotherapy in advanced thymic epithelial tumors: a case series.	Frontiers in immunology	doi: 10.3389/fimmu.2025.1516297
40496850	2025	Ji K, Guo L, Zuo D, Feng M, Chen X, Zhao Z, Tang J, Chen G	Harnessing delta-like ligand 3: bridging biomarker discovery to next-generation immunotherapies in refractory small cell lung cancer.	Frontiers in immunology	doi: 10.3389/fimmu.2025.1592291
40496725	2025 Jun	Chen R, Duan B, Li S, Zhu Y, Huang Z, Shen D, Ye Z, Yan Y, Qiu C, Guan H, Yao Y, Dong J, Wu F, Jiang X, Shi X, Kou L	A triple-targeting "nano-brake" remodeling the impaired immune microenvironment in skin lesions for psoriasis treatment.	Materials today. Bio	doi: 10.1016/j.mtbio.2025.101875
40496627	2025 Sep	Du J, Luo C, Liu Y, Tan W, Wang K, Chi J, Liu L, Xu Y, Tang Z, Chen X	PD-L1-targeted polymer-peptide-immune nanomedicine synergizes radiotherapy for durable tumor control.	Bioactive materials	doi: 10.1016/j.bioactmat.2025.05.017
40496608	2025	Yu X, Zhao W, Feng Q, Tian J, Zhao L, Xiao J, Wei H	Complete remission in PD-L1 high expression advanced gastric cancer patient with PD-L1 immunotherapy and chemotherapy integration treatment strategy: a case report.	Frontiers in oncology	doi: 10.3389/fonc.2025.1507411
40496311	2025	Carvalho Gouveia M, Colombo Bonadio R, Lazar Neto F, Spagnol Trento MM, Trinconi Cunha M, Scaranti M	PD-1 or PD-L1 inhibitors in addition to first-line chemotherapy for endometrial cancer: an extracted individual patient data meta-analysis.	Ecancermedicalscience	doi: 10.3332/ecancer.2025.1884
40495695	2025 Jun 11	Wang H, Zhan H, Pan B, Zeng L, Chen Z, Liu S, Zhang Q, Hong X, Lu J, Lin X, Zhao X, Lai J, Jie K, Li Y, Zhong J, Peng S, Chen S, Chen C, Zhong W, Wu S, Pan Y, Lin T, Chen X	Engineering CRISPR System-Based Bacterial Outer Membrane Vesicle Potentiates T Cell Immunity for Enhanced Cancer Immunotherapy.	Advanced materials (Deerfield Beach, Fla.)	doi: 10.1002/adma.202501565
40495489	2025 Jun 11	Sim HI, Jo Y, Ahn H, Hong J, Kim HB, Yun B, Son H, Jeong Y, Kim J, Park CS, Park Y, Jin HS	Modulating CD226 and PD-(L)1 pathways improves CMV-specific CD8＋T cell responses in the absence of IL-2.	BMB reports	pii: 6479
40495210	2025 Jun 10	Wang J, Xu Y, Hong B, Hou Q, Chen W, Zhang W, Zheng W	PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone as the first line treatment for advanced biliary tract cancer: a pooled analysis of KEYNOTE-966 and TOPAZ-1 trails.	World journal of surgical oncology	doi: 10.1186/s12957-025-03877-0
40495175	2025 Jun 10	Gao S, Song Y	Clinical pathological and molecular features of 100 patients with gastric-type cervical adenocarcinoma.	Diagnostic pathology	doi: 10.1186/s13000-025-01666-7
40495151	2025 Jun 10	Yu J, Xu H, Xiong F, Liu X, Lingfei M, Gao H, Li Y	Lipidomics reveals biomarkers of the efficacy of first-line ICI therapy combined with chemotherapy in NSCLC.	Journal of translational medicine	doi: 10.1186/s12967-025-06542-y
40494858	2025 Jun 10	Zhang R, Cheng S, Sun K, Zhang L, Yan X, Yang F	Case report: a R0 resection successfully induced by T-DXd plus PD-1 inhibitor regimen in a primary unresectable stage IIIB NSCLC with ERBB2-mutation.	NPJ precision oncology	doi: 10.1038/s41698-025-00982-x
40494842	2025 Jun 10	Piyawajanusorn C, Ghislat G, Ballester PJ	Predicting atezolizumab response in metastatic urothelial carcinoma patients using machine learning on integrated tumour gene expression and clinical data.	NPJ precision oncology	doi: 10.1038/s41698-025-00969-8
40494752	2025 May 22	Peruzzo N, Lenz G, Akhiwu T, Bilalaga M, Gaddipati GN, Müller NLF, Zarpellon L, Venero F, Corassa M, Cardona AF, Reuss JE, Pellini B	Chemotherapy Plus Anti-PD-1 or Anti-PD-L1 in Advanced PD-L1-Negative Squamous Cell Lung Carcinoma: A Systematic Review and Meta-Analysis.	Clinical lung cancer	pii: S1525-7304(25)00076-2. doi: 10.1016/j.cllc.2025.04.006
40494207	2025 Jun 9	Jiang Y, Yu Z, Wang J, Wu Y, Li Z, Le T, Yang C, Wei Y, Zhang G, Ma H	Targeting USP47 enhances immunotherapy in hepatocellular carcinoma by destabilizing PD-L1.	International immunopharmacology	doi: 10.1016/j.intimp.2025.115024
40493365	2025 Jun 2	Tan J, Yang SC, Dinan MA, Chiang AC, Gross CP, Wang SY	Biomarker-Specific Survival and Medication Cost for Patients With Non-Small Cell Lung Cancer.	JAMA network open	doi: 10.1001/jamanetworkopen.2025.14519
40493058	2025 Jun 10	Piao H, Wenping L, Chengde L, Haoming L, Xiaohan Z, Yingdi L, Xuezheng Z, Shumei M	The efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone in advanced or metastatic gastric or gastroesophageal junction cancer: a meta-analysis of randomized controlled trials.	European journal of clinical pharmacology	doi: 10.1007/s00228-025-03861-3
40492492	2025 Jun 10	Zhang M, Zhang X, Wang C, Mu M, Ren K, Ni N, Yip LX, Guo K, Hu X, Teng F, Leong DT, Fan Q, Sun X	Convertible ROS Nanocatalyst/Eliminator for Enhancing Tumor Radio-Immunotherapy and Relieving Radiation Enteritis.	Advanced science (Weinheim, Baden-Wurttemberg, Germany)	doi: 10.1002/advs.202503602
40491684	2025	Hatakeyama Y, Mizugaki H, Yamada N, Mizukami Y, Kuwahara K, Asahina H, Adachi H, Yokouchi H, Matsuno Y, Oizumi S	Response of EGFR-mutated pulmonary pleomorphic carcinoma to pembrolizumab.	Respiratory medicine case reports	doi: 10.1016/j.rmcr.2025.102234
40491506	2025	Dong P, Zhang S, Zhang Y, Hu H, Zhou Q, Liu Y, Mao Z	Dual-Active Nanoimmunomodulators for the Synergistic Enhancement of the Antitumor Efficacy of Photodynamic Immunotherapy.	Biomaterials research	doi: 10.34133/bmr.0214
40491119	2025 Jun	Li GX, Zheng QM, Li YY, Wang YP, Zhang M, Sun ZG	Correlation of Peripheral Blood CD4/CD8 Ratio with Efficacy and Prognosis in Patients with Non-Small Cell Lung Cancer Receiving PD-1/PD-L1 Inhibitors.	Journal of the College of Physicians and Surgeons--Pakistan : JCPSP	doi: 10.29271/jcpsp.2025.06.800
40490951	2025 Jun 9	Gao F, You W, Zhang L, Shen AZ, Chen G, Zhang Z, Nie X, Xia L, Huang WQ, Wang LH, Hong CY, Yin DL, You YZ	Correction to "Copper Chelate Targeting Externalized Phosphatidylserine Inhibits PD-L1 Expression and Enhances Cancer Immunotherapy".	Journal of the American Chemical Society	doi: 10.1021/jacs.5c07516
40490909	2025 Jun	Cheng B, Liu T, Cao H, Liu J, Ren Y, Huang J, Kong D, Chen T, Liu Y, Chen J	Discovery of Small Molecule PD-L1 Inhibitors via Optimization of Solvent-Interaction Region for Cancer Immunotherapy.	Chemical biology & drug design	doi: 10.1111/cbdd.70141
40490504	2025 Jun 10	Li Y, Yuan X, Yin XF, Zheng D, Shi F, Liu D, Hu L, Shi X, Wen N, He QY, Yang H, Zhang CZ	Proteomics analysis and immune profiling reveal regulators of PD-L1 in oesophageal squamous cell carcinoma.	British journal of cancer	doi: 10.1038/s41416-025-03068-4
40489506	2025	Matalon O, Perissinotto A, Baruch K, Braiman S, Geiger Maor A, Yoles E, Wilczynski E, Nevo U, Priel A	Agent-based modeling for personalized prediction of an experimental immune response to immunotherapeutic antibodies.	PloS one	doi: 10.1371/journal.pone.0324618
40489241	2025 Jun 9	Katan Piñeiro J, Soto AS, Farias A, Perrone Sibilia M, Sanchez VR, Martin V, Berguer PM, Seigelshifer DJ, Martín Fenoy I, Goldman A	Modulating Dendritic Cell function in Allergic Asthma with Toxoplasma gondii serine-protease inhibitor 1.	International immunology	pii: dxaf034. doi: 10.1093/intimm/dxaf034
40489082	2025 Jun 6	Stockem CF, Gil-Jimenez A, Ali H, van Dorp J, van Dijk N, van Montfoort ML, Alkemade M, Broeks A, Seignette IM, Hooijberg E, Brugman W, Voogd R, van Rhijn BWG, Mertens LS, Feijter JM, Mehra N, van der Heijden AG, Meijer RP, Suelmann BBM, Scheper W, Wessels LFA, Vis DJ, van der Heijden MS	Biomarker analysis and treatment dynamics following preoperative ipilimumab plus nivolumab in locally advanced urothelial cancer from the phase 1B NABUCCO study.	Clinical cancer research : an official journal of the American Association for Cancer Research	doi: 10.1158/1078-0432.CCR-25-0419
40489040	2025 Jun 9	Han ZY, Zhang C, An JX, Wang YZ, Zeng X, Zhang XZ	Directly Evolved Nanovaccines Modulate Disrupted Circadian Rhythm and Enhance Cancer Immunotherapy.	Advanced materials (Deerfield Beach, Fla.)	doi: 10.1002/adma.202502602
40488559	2025 Jun 9	Zhou Z, Liu Q, Zhang G, Mohammed D, Amadou S, Tan G, Zhang X	RETRACTED: Zhou et al. HOXA11-AS1 Promotes PD-L1-Mediated Immune Escape and Metastasis of Hypopharyngeal Carcinoma by Facilitating PTBP1 and FOSL1 Association. Cancers 2022, 14, 3694.	Cancers	doi: 10.3390/cancers17121917
40488300	2025 Jun 9	Lee LH, Xu X, Mourikis T, Tang F, Fairchild L, Ji L, Grauel AL, Wagner JP, Szpakowski S, Pelletier MR, Kattenhorn L, Sansregret L, Costa C, Bossen C, Burks H, Farago AF, Wu J	Defining non-small cell lung cancer tumor microenvironment changes at primary and acquired immune checkpoint inhibitor resistance using clinical and real-world data.	Cancer research communications	doi: 10.1158/2767-9764.CRC-24-0605
40488279	2025 Jun	Wang L, Wu J, Shao P, Bao W, Mao L, Pan Z, Bao A, Zhang M, Wu Z, Fan G	An Advanced IVB Lung Adenocarcinoma Patient With KRAS Mutations, Benefited From Camrelizumab Combined With Anti-Angiogenic Agents for Therapy: A Case Report.	Cancer reports (Hoboken, N.J.)	doi: 10.1002/cnr2.70186
40487954	2025 May 15	Xu M, Ruan TT, Tang H, Fang RF, Sai WL, Xie Q, Yao DF, Yao M	Up-regulated programmed cell death protein-1/its ligand 1 expression promotes metabolic dysfunction-associated steatotic liver disease malignant progression.	World journal of gastrointestinal oncology	doi: 10.4251/wjgo.v17.i5.104842
40487669	2025 May	Wang Z, Yin R, Zhang L, Li S, Zhou Z, Sun M	Sulfafurazole dimers potentiate chemo-immunotherapy of low immunogenic breast cancer by preventing the PD-L1 exosomes secretion.	Acta pharmaceutica Sinica. B	doi: 10.1016/j.apsb.2025.03.007
40487665	2025 May	Zhang Y, Zhao W, Wu L, Ai T, He J, Chen Z, Wang C, Wang H, Zhou R, Liu C, Zhao L	Inhibition of CCT5-mediated asparagine biosynthesis and anti-PD-L1 produce synergistic antitumor effects in colorectal cancer.	Acta pharmaceutica Sinica. B	doi: 10.1016/j.apsb.2025.03.026
40487643	2025 May	Zhang Y, Jin W, Deng Z, Gao B, Zhu Y, Fu J, Xu C, Wang W, Bai T, Jiao L, Wu H, Zhang M, Zhang M	Metabolic reprogramming nanomedicine potentiates colon cancer sonodynamic immunotherapy by inhibiting the CD39/CD73/ADO pathway.	Acta pharmaceutica Sinica. B	doi: 10.1016/j.apsb.2025.03.046
40487560	2025 Jan-Dec	Alrefai Y, Wadhwani S, Wadhwani N, Bangolo A, Mizrahi J, Feldman T	Primary Mediastinal Large B-cell Lymphoma: A Diagnostic Conundrum.	Case reports in oncology	doi: 10.1159/000545931
40487483	2025 Jun 18	David M, Schiele P, Monteferrario D, Saviane G, Martelli AE, Dupont CF, Jeanneau C, Marchetti I, Tadi SK, Vahldick J, Truong LN, Zhou Y, Sauer IM, Schöning W, Na IK, Reik A, Frentsch M, Rosa M, Fenard D	Enhanced anti-tumor activity by zinc finger repressor-driven epigenetic silencing of immune checkpoints and TGFBR2 in CAR-T cells and TILs.	Molecular therapy. Oncology	doi: 10.1016/j.omton.2025.200989
40487169	2025 Jun	Zhang H, Liang Y, Deng S, Du J	Integrating gene demethylation and immune modulation: PD-1 nanovesicles as a dual-action therapy for NSCLC.	Materials today. Bio	doi: 10.1016/j.mtbio.2025.101851
40487160	2025 Jun	Wang L, Li J, Zhang D, Tan S, Jiang G, Wang X, Li F, Zhou Y, Chen P, Wei R, Xi L	TMTP1-modified polymeric micelles for the inhibition of ovarian cancer metastasis and recurrence through enhanced photothermal-immunotherapy.	Materials today. Bio	doi: 10.1016/j.mtbio.2025.101825
40486834	2025 Apr	Fang Y, Zhu Y, Wang W, Xia Z, He S, Dong G, Sheng C	GPC3-mediated lysosome-targeting chimeras (GLTACs) for targeted degradation of membrane proteins.	Acta pharmaceutica Sinica. B	doi: 10.1016/j.apsb.2025.02.037
40486515	2025	Huang L, Xu Y, Liu N, Chen H, Wu Z, Li Q, Lu M, Wei W, Zhang Y, Chen M, Xu L, Shi M, Lai Z	Lenvatinib versus bevacizumab when combined with PD-1/L1 inhibitor and hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma.	Frontiers in immunology	doi: 10.3389/fimmu.2025.1573098
40486166	2025	Calis U, Aydogan M, Seval GC, Dalva K, Toprak SK	Impact of PD-1 and PD-L1 expression on treatment outcomes in newly diagnosed acute myeloid leukemia patients.	Leukemia research reports	doi: 10.1016/j.lrr.2025.100514
40485488	2025 Jun 9	Mallick AM, Chatterjee A, Gurung AB, Uttarasili P, Tripathi A, Hembram M, Srivastava A, Sinha Roy R	Designed gramicidin-inspired stabilized peptide-based therapeutics to potentiate immunotherapy against aggressive kidney cancer.	Biomaterials science	doi: 10.1039/d5bm00109a
40485406	2025 Jun 7	Anwer MA, Sinha R, Bharti S, Surabhi, Kumar T, Singh A	Clinicopathological association of programmed death-ligand 1 (PD-L1) expression in uterine cervical carcinomas: A cross-sectional observational study.	Indian journal of pathology & microbiology	doi: 10.4103/ijpm.ijpm_572_24
40483667	2025 Jun 8	Sinha A, Ghosh D, Karati D	Tumor microenvironment and immunotherapy: from bench to bedside.	Medical oncology (Northwood, London, England)	doi: 10.1007/s12032-025-02818-x
40483449	2025 Jun 7	Wang X, Fu X, Liu Q, Li J, Ge Y, Zhang J, Wang S, Wang L, Wang D, Sun Y, Gan Y, Sun H, Wang Z, Sun Y, Gao A	Impact of irae characteristics on efficacy of consolidative immunotherapy following chemoradiotherapy in locally advanced NSCLC.	BMC pulmonary medicine	doi: 10.1186/s12890-025-03742-6
40483310	2025 Jun 7	Li Y, Zhu J, Zhai F, Ge Y, Zhan Z, Wang S, Kong L, Zhao J, Hu L, Wang S, Shi J, Mao J, Yu Z, Wang H, Jin J, Zhao M, Li H, Jin X	LMNB2-mediated high PD-L1 transcription triggers the immune escape of hepatocellular carcinoma.	Cell death discovery	doi: 10.1038/s41420-025-02540-7
40483270	2025 Jun 7	Kimura A, Mitsuda J, Yoshimura K, Saburi S, Murakami N, Sakurai N, Yoshizawa K, Morimoto H, Mukudai S, Nagao H, Ogi H, Shibata S, Miyagawa-Hayashino A, Konishi E, Itoh K, Hirano S, Tsujikawa T	Neoadjuvant therapy-induced immune dynamics and myeloid-associated resistance in advanced head and neck cancer.	NPJ precision oncology	doi: 10.1038/s41698-025-00954-1
40482974	2025 Jun 5	Canossi A, Vistoli F, Sebastiani P, Colanardi A, Del Beato T, Panarese A	Serum PD-L1 and CTLA-4 levels as biomarkers of acute rejection and renal dysfunction in kidney transplant recipients.	Transplant immunology	doi: 10.1016/j.trim.2025.102250
40482003	2025 Jun 7	Green MF, Wallen ZD, Ko HC, Strickland KC, Dillard A, Conroy JM, Dash DP, Nesline MK, DePietro P, Zhang S, Saini KS, Sathyan P, Eisenberg M, Caveney B, Ramkissoon S, Severson EA, Previs RA	Utilization of a Multi-modal Comprehensive Genomic and Immune Profiling Testing Strategy Results in a High Rate of Test Success and Detection of Clinically Relevant Biomarkers While Optimizing Tissue Usage.	Molecular diagnosis & therapy	doi: 10.1007/s40291-025-00793-7
40481961	2025 Jun 7	Piermattei A, Migliara G, Feraco A, Bruno C, Cioni L, Zhang Q, Padial-Urtueta B, Merenda E, Fadda G, Raffaelli M, Larocca LM, Mule A, Pontecorvi A, Rossi ED	Evaluation of PD-L1, TERT promoter mutations, and BRAFV600E mutation in poorly differentiated, differentiated high grade thyroid carcinoma and anaplastic carcinoma of the thyroid: our institutional experience.	Virchows Archiv : an international journal of pathology	doi: 10.1007/s00428-025-04134-1
40481544	2025 Jun 6	Nikonezhad B, Lotfian M, Manavi N, Zamani A, Mahdevar M	Insights into the E2F target genes in breast cancer: associations of pathway genes with prognosis and immune cell filtration based on in silico and ex vivo analyses.	Cancer cell international	doi: 10.1186/s12935-025-03839-2
40480558	2025 Jun 4	Luo Y, Wang X, Li Y, Duan D, Liu K, Lei M, Zhang L, Zhu Y	Carrier-free Nanotherapeutics unleashed: Ce6/siPD-L1 co-delivery system synergizes photodynamic and RNAi therapies to combat breast cancer.	International journal of biological macromolecules	doi: 10.1016/j.ijbiomac.2025.144962
40480146	2025 Aug	Shen W, Li Z, Huang J, Zhang G, Tang Y, Fan W, Li J	Development and validation of nomogram including mutations in angiogenesis-related genes as risk factors for HCC patients treated with TACE.	Translational oncology	doi: 10.1016/j.tranon.2025.102437
40480079	2025 May 29	Yang C, Xu Y, Lin Z, Zhang A, Li L, Ye Z, Zhang Q, Hu H, Ren G, Cheng P, Wang Z, Wang O	Spatial discovery of pyrotinib overcoming HER2-positive breast cancer resistance by breaking fibroblast-induced immune barriers.	Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy	doi: 10.1016/j.drup.2025.101261
40479646	2025 Jun 6	Dharini AG, Kejamurthy P, Ramya Devi KT	Co-regulation of miRNA and lncRNA on immunosuppression gene: unveiling the regulatory networks in cancer.	Nucleosides, nucleotides & nucleic acids	doi: 10.1080/15257770.2025.2514129
40476645	2025 Jun 6	Petrelli F, Ghidini A, Sarno I, Iaculli A, Irene A, Moleri G, Rossitto M, Dottorini L	Adding immune checkpoint inhibitors to chemotherapy in elderly cancer patients: Beneficial for many but not all?	Tumori	doi: 10.1177/03008916251328539
40475857	2025 Jun	Yuan W, Jiang X, Qin J, Wang S, Liu M, Jin J, Geng F, Pan X, Zhang J	A smart all-in-one strategy based on hybrid bacteria with targeting drug delivery and spatiotemporal drug release to boost the synergistic therapeutic efficacy against TNBC.	Materials today. Bio	doi: 10.1016/j.mtbio.2025.101849
40475838	2025 Jun	Alhariri B, Elfatih A, Elhassan OO, Elfatih M, Kheir AM, Elkhatib R	Lung Adenocarcinoma With Extensive Vascular Invasion and Retinal Metastasis: A Case Report.	Respirology case reports	doi: 10.1002/rcr2.70170
40475779	2025	Ferreira CA, Potluri HK, Mahmoudian M, Massey CF, Grudzinski JJ, Carston AM, Clemons NB, Idrissou MB, Thickens AS, Rosenkrans ZT, Choi C, Kerr CP, Pinchuk AN, Kwon O, Jeffery JJ, Bednarz BP, Morris ZS, Weichert JP, McNeel DG, Hernandez R	Immunomodulatory effects of alpha vs beta radiopharmaceutical therapy in murine prostate cancer.	Frontiers in immunology	doi: 10.3389/fimmu.2025.1563387
40475777	2025	Wang S, Wang Z, Liu M, Sun X	Role of extracellular vesicles in cancer: implications in immunotherapeutic resistance.	Frontiers in immunology	doi: 10.3389/fimmu.2025.1581635
40475772	2025	Agustoni F, Yu H, Ellison K, Smith D, Mitchell P, Rivalland G, Dziadziuszko R, Gao D, Ren S, Rivard CJ, San Millan I, Corallo S, Pedrazzoli P, Hirsch FR	Indoleamine 2,3-dioxygenase-1 expression in non-small-cell lung cancer: analyses of prevalence, clinical correlations and prognostic impact in 2 large patient cohorts.	Frontiers in immunology	doi: 10.3389/fimmu.2025.1586782
40475760	2025	Tang P, Han Z, Zhao Y, Xu T, Zhang Y, Zhu L, Song F, Gao C, Gong J, Cheng J, Wang C, Wang T, Xu J, Wang Y, Chen Z	ALG3 as a prognostic biomarker and mediator of PD-1 blockade resistance in hepatocellular carcinoma.	Frontiers in immunology	doi: 10.3389/fimmu.2025.1589153
40475652	2025 May 22	Johnson RM, Wang S, Carozza JA, Fernandez D, Scicinski J, Verity NA, Mardjuki R, Cao X, Papkoff J, Ray N, Li L	ENPP1 inhibitor with ultralong drug-target residence time as an innate immune checkpoint blockade cancer therapy.	bioRxiv : the preprint server for biology	pii: 2025.05.18.654655. doi: 10.1101/2025.05.18.654655
40475251	2025	Yang H, Yang L, Liu Y, Wang L	Adebrelimab in Small Cell Lung Cancer: From Current Advances to Emerging Combination Strategy and Challenge.	Biologics : targets & therapy	doi: 10.2147/BTT.S500470
40474706	2025 Apr	Ascione A, Botticelli A, Leopizzi M, Cerbelli E, Cirillo A, Bellavia D, Della Rocca C, d'Amati G, Cerbelli B	Immunotherapy in recurrent/metastatic head and neck squamous cell carcinoma: PD-L1 and beyond.	Pathologica	doi: 10.32074/1591-951X-1092
40474015	2025 Jun 6	Xiao J, Xia Z, Wu Z, Fang M	Clinical features, treatment, and outcomes of anti-PD-L1 induced psoriasis.	Investigational new drugs	doi: 10.1007/s10637-025-01554-3
40473974	2025 Jun 5	Qin K, Gay CM, Byers LA, Zhang J	The current and emerging immunotherapy paradigm in small-cell lung cancer.	Nature cancer	doi: 10.1038/s43018-025-00992-5
40473613	2025 Jun 5	Sun S, Chen J, Jiang S, Zhao Y, Wu T, Yan C, Li J, Zhang Y, Wang H	Macrocyclization of Unprotected Peptides via Cycloaddition between o-Diones and Furan-2(3H)-one.	Organic letters	doi: 10.1021/acs.orglett.5c01853
40473310	2025 Jun 5	Fennell É, Taylor GS, Leahy CI, Ross AM, Reynolds G, Perry T, Youd E, Skidmore J, Ramzi R, Darwish R, Hunter KJ, Willcox BE, Jermann P, Arif Jahangir C, Rahman A, Gallagher WM, Nikulina N, Ben Cheikh B, Braubach O, Mayer AT, Young LS, Grammatopoulos D, Faustini S, Richter A, Dowell AC, Venith T, Thein OS, Parekh D, Belchamber KBR, Thickett DR, Scott A, Attanoos R, Mundo L, Lazzi S, Leoncini L, Leopold G, Steven N	Multi-omic spatial profiling reveals the unique SARS-CoV-2 lung microenvironment and collagen VI as a predictive biomarker in severe COVID-19.	The European respiratory journal	pii: 2301699. doi: 10.1183/13993003.01699-2023
40473109	2025 Jun 3	Leighl NB, Paz-Ares L, Abreu DR, Hui R, Baka S, Bigot F, Nishio M, Smolin A, Ahmed S, Schoenfeld AJ, Daher S, Cortinovis DL, Di Noia V, Linardou H, Gainor JF, Dutcus C, Okpara CE, Deng X, Kush D, Arunachalam A, Song A, Cho BC	LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti-PD-(L)1 Plus Platinum Chemotherapy.	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	pii: S1556-0864(25)00750-6. doi: 10.1016/j.jtho.2025.05.020
40473108	2025 Jun 3	Peters S, Regan MM, Paz-Ares LG, Reck M, Borghaei H, O'Byrne KJ, Brahmer JR, Penrod JR, Li J, Tracy L, Yuan Y, Bushong J, Lee A, Eccles LJ, Ray S, Ramalingam SS	Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic Non-small Cell Lung Cancer Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1.	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	pii: S1556-0864(25)00749-X. doi: 10.1016/j.jtho.2025.05.019
40472843	2025 May 24	Xie G, Gao L, Lu R, Tian L, Zheng T, Li X, Dang Y, Cole PA, Yu X, Jiang H, Chen Z	Biochemical analysis of PD-L1 ubiquitination by CRL3(SPOP), ARIH1, and NEDD4 family ubiquitin ligases.	Structure (London, England : 1993)	pii: S0969-2126(25)00183-2. doi: 10.1016/j.str.2025.05.005
40472683	2025 Jun 2	Caputo A, Angerilli V, Gambella A, L'Imperio V, Perrone G, Taffon C, Milione M, Grillo F, Mastracci L, Vanoli A, Parente P, Fassan M	Immunohistochemical biomarker scoring in gastroesophageal cancers: Can computers help us?	Pathology, research and practice	doi: 10.1016/j.prp.2025.156068
40472682	2025 Jun 4	Liang G, Ma Y, Deng P, Li S, He C, He H, Liu H, Fan Y, Li Z	Hexokinases in gastrointestinal cancers: From molecular insights to therapeutic opportunities.	Seminars in oncology	doi: 10.1016/j.seminoncol.2025.152351
